Neuroendocrine and neurotrophic signaling in Huntington's disease: Implications for pathogenic mechanisms and treatment strategies

Danielle M. Bartlett, Travis M. Cruickshank, Anthony J. Hannan, Peter R. Eastwood, Alpar S. Lazar, Melanie Ziman

    Research output: Contribution to journalReview article

    11 Citations (Scopus)
    100 Downloads (Pure)

    Abstract

    Huntington's disease (HD) is a fatal neurodegenerative disease caused by an extended polyglutamine tract in the huntingtin protein. Circadian, sleep and hypothalamic-pituitary-adrenal (HPA) axis disturbances are observed in HD as early as 15 years before clinical disease onset. Disturbances in these key processes result in increased cortisol and altered melatonin release which may negatively impact on brain-derived neurotrophic factor (BDNF) expression and contribute to documented neuropathological and clinical disease features. This review describes the normal interactions between neurotrophic factors, the HPA-axis and circadian rhythm, as indicated by levels of BDNF, cortisol and melatonin, and the alterations in these intricately balanced networks in HD. We also discuss the implications of these alterations on the neurobiology of HD and the potential to result in hypothalamic, circadian, and sleep pathologies. Measurable alterations in these pathways provide targets that, if treated early, may reduce degeneration of brain structures. We therefore focus here on the means by which multidisciplinary therapy could be utilised as a non-pharmaceutical approach to restore the balance of these pathways.

    Original languageEnglish
    Pages (from-to)444-454
    Number of pages11
    JournalNeuroscience and Biobehavioral Reviews
    Volume71
    DOIs
    Publication statusPublished - 1 Dec 2016

    Fingerprint

    Huntington Disease
    Brain-Derived Neurotrophic Factor
    Melatonin
    Hydrocortisone
    Sleep
    Neurobiology
    Nerve Growth Factors
    Therapeutics
    Circadian Rhythm
    Neurodegenerative Diseases
    Pathology
    Brain

    Cite this

    @article{e0ec6eaffa9f4ebca3cd1c724f8f6e08,
    title = "Neuroendocrine and neurotrophic signaling in Huntington's disease: Implications for pathogenic mechanisms and treatment strategies",
    abstract = "Huntington's disease (HD) is a fatal neurodegenerative disease caused by an extended polyglutamine tract in the huntingtin protein. Circadian, sleep and hypothalamic-pituitary-adrenal (HPA) axis disturbances are observed in HD as early as 15 years before clinical disease onset. Disturbances in these key processes result in increased cortisol and altered melatonin release which may negatively impact on brain-derived neurotrophic factor (BDNF) expression and contribute to documented neuropathological and clinical disease features. This review describes the normal interactions between neurotrophic factors, the HPA-axis and circadian rhythm, as indicated by levels of BDNF, cortisol and melatonin, and the alterations in these intricately balanced networks in HD. We also discuss the implications of these alterations on the neurobiology of HD and the potential to result in hypothalamic, circadian, and sleep pathologies. Measurable alterations in these pathways provide targets that, if treated early, may reduce degeneration of brain structures. We therefore focus here on the means by which multidisciplinary therapy could be utilised as a non-pharmaceutical approach to restore the balance of these pathways.",
    keywords = "Brain-derived neurotrophic factor (BDNF), Circadian rhythm, Hypothalamic-pituitary-adrenal (HPA) axis, Hypothalamus, Sleep, Suprachiasmatic nucleus (SCN)",
    author = "Bartlett, {Danielle M.} and Cruickshank, {Travis M.} and Hannan, {Anthony J.} and Eastwood, {Peter R.} and Lazar, {Alpar S.} and Melanie Ziman",
    year = "2016",
    month = "12",
    day = "1",
    doi = "10.1016/j.neubiorev.2016.09.006",
    language = "English",
    volume = "71",
    pages = "444--454",
    journal = "Neuroscience & Biobehavioral Reviews",
    issn = "0149-7634",
    publisher = "Elsevier",

    }

    Neuroendocrine and neurotrophic signaling in Huntington's disease : Implications for pathogenic mechanisms and treatment strategies. / Bartlett, Danielle M.; Cruickshank, Travis M.; Hannan, Anthony J.; Eastwood, Peter R.; Lazar, Alpar S.; Ziman, Melanie.

    In: Neuroscience and Biobehavioral Reviews, Vol. 71, 01.12.2016, p. 444-454.

    Research output: Contribution to journalReview article

    TY - JOUR

    T1 - Neuroendocrine and neurotrophic signaling in Huntington's disease

    T2 - Implications for pathogenic mechanisms and treatment strategies

    AU - Bartlett, Danielle M.

    AU - Cruickshank, Travis M.

    AU - Hannan, Anthony J.

    AU - Eastwood, Peter R.

    AU - Lazar, Alpar S.

    AU - Ziman, Melanie

    PY - 2016/12/1

    Y1 - 2016/12/1

    N2 - Huntington's disease (HD) is a fatal neurodegenerative disease caused by an extended polyglutamine tract in the huntingtin protein. Circadian, sleep and hypothalamic-pituitary-adrenal (HPA) axis disturbances are observed in HD as early as 15 years before clinical disease onset. Disturbances in these key processes result in increased cortisol and altered melatonin release which may negatively impact on brain-derived neurotrophic factor (BDNF) expression and contribute to documented neuropathological and clinical disease features. This review describes the normal interactions between neurotrophic factors, the HPA-axis and circadian rhythm, as indicated by levels of BDNF, cortisol and melatonin, and the alterations in these intricately balanced networks in HD. We also discuss the implications of these alterations on the neurobiology of HD and the potential to result in hypothalamic, circadian, and sleep pathologies. Measurable alterations in these pathways provide targets that, if treated early, may reduce degeneration of brain structures. We therefore focus here on the means by which multidisciplinary therapy could be utilised as a non-pharmaceutical approach to restore the balance of these pathways.

    AB - Huntington's disease (HD) is a fatal neurodegenerative disease caused by an extended polyglutamine tract in the huntingtin protein. Circadian, sleep and hypothalamic-pituitary-adrenal (HPA) axis disturbances are observed in HD as early as 15 years before clinical disease onset. Disturbances in these key processes result in increased cortisol and altered melatonin release which may negatively impact on brain-derived neurotrophic factor (BDNF) expression and contribute to documented neuropathological and clinical disease features. This review describes the normal interactions between neurotrophic factors, the HPA-axis and circadian rhythm, as indicated by levels of BDNF, cortisol and melatonin, and the alterations in these intricately balanced networks in HD. We also discuss the implications of these alterations on the neurobiology of HD and the potential to result in hypothalamic, circadian, and sleep pathologies. Measurable alterations in these pathways provide targets that, if treated early, may reduce degeneration of brain structures. We therefore focus here on the means by which multidisciplinary therapy could be utilised as a non-pharmaceutical approach to restore the balance of these pathways.

    KW - Brain-derived neurotrophic factor (BDNF)

    KW - Circadian rhythm

    KW - Hypothalamic-pituitary-adrenal (HPA) axis

    KW - Hypothalamus

    KW - Sleep

    KW - Suprachiasmatic nucleus (SCN)

    UR - http://www.scopus.com/inward/record.url?scp=84991821910&partnerID=8YFLogxK

    U2 - 10.1016/j.neubiorev.2016.09.006

    DO - 10.1016/j.neubiorev.2016.09.006

    M3 - Review article

    VL - 71

    SP - 444

    EP - 454

    JO - Neuroscience & Biobehavioral Reviews

    JF - Neuroscience & Biobehavioral Reviews

    SN - 0149-7634

    ER -